Michael Stratton

Summary

Affiliation: Wellcome Trust Genome Campus
Country: UK

Publications

  1. doi request reprint Genome resequencing and genetic variation
    Michael Stratton
    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
    Nat Biotechnol 26:65-6. 2008
  2. pmc Signatures of mutational processes in human cancer
    Ludmil B Alexandrov
    Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK
    Nature 500:415-21. 2013
  3. pmc Complex landscapes of somatic rearrangement in human breast cancer genomes
    Philip J Stephens
    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
    Nature 462:1005-10. 2009
  4. pmc Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
    Gijs van Haaften
    Wellcome Trust Sanger Institute, Hinxton, UK
    Nat Genet 41:521-3. 2009
  5. pmc Deciphering signatures of mutational processes operative in human cancer
    Ludmil B Alexandrov
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
    Cell Rep 3:246-59. 2013
  6. pmc Mutational processes molding the genomes of 21 breast cancers
    Serena Nik-Zainal
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
    Cell 149:979-93. 2012
  7. pmc Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer
    Elizabeth P Murchison
    Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, UK
    Cell 148:780-91. 2012
  8. pmc Somatic structural rearrangements in genetically engineered mouse mammary tumors
    Ignacio Varela
    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB101SA, UK
    Genome Biol 11:R100. 2010
  9. pmc RNA editing of human microRNAs
    Matthew J Blow
    Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK
    Genome Biol 7:R27. 2006
  10. doi request reprint Exploring the genomes of cancer cells: progress and promise
    Michael R Stratton
    Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK
    Science 331:1553-8. 2011

Collaborators

Detail Information

Publications15

  1. doi request reprint Genome resequencing and genetic variation
    Michael Stratton
    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
    Nat Biotechnol 26:65-6. 2008
  2. pmc Signatures of mutational processes in human cancer
    Ludmil B Alexandrov
    Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK
    Nature 500:415-21. 2013
    ..The results reveal the diversity of mutational processes underlying the development of cancer, with potential implications for understanding of cancer aetiology, prevention and therapy. ..
  3. pmc Complex landscapes of somatic rearrangement in human breast cancer genomes
    Philip J Stephens
    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
    Nature 462:1005-10. 2009
    ..The study provides a new perspective on cancer genomes, highlighting the diversity of somatic rearrangements and their potential contribution to cancer development...
  4. pmc Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
    Gijs van Haaften
    Wellcome Trust Sanger Institute, Hinxton, UK
    Nat Genet 41:521-3. 2009
    ..UTX reintroduction into cancer cells with inactivating UTX mutations resulted in slowing of proliferation and marked transcriptional changes. These data identify UTX as a new human cancer gene...
  5. pmc Deciphering signatures of mutational processes operative in human cancer
    Ludmil B Alexandrov
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
    Cell Rep 3:246-59. 2013
    ..Our approach provides a basis for characterizing mutational signatures from cancer-derived somatic mutational catalogs, paving the way to insights into the pathogenetic mechanism underlying all cancers...
  6. pmc Mutational processes molding the genomes of 21 breast cancers
    Serena Nik-Zainal
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
    Cell 149:979-93. 2012
    ..The mechanisms underlying most of these mutational signatures are unknown. However, a role for the APOBEC family of cytidine deaminases is proposed...
  7. pmc Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer
    Elizabeth P Murchison
    Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, UK
    Cell 148:780-91. 2012
    ....
  8. pmc Somatic structural rearrangements in genetically engineered mouse mammary tumors
    Ignacio Varela
    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB101SA, UK
    Genome Biol 11:R100. 2010
    ..These were models of Trp53-mutated breast cancer, Brca1- and Brca2-associated hereditary breast cancer, and E-cadherin (Cdh1) mutated lobular breast cancer...
  9. pmc RNA editing of human microRNAs
    Matthew J Blow
    Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK
    Genome Biol 7:R27. 2006
    ..MicroRNAs (miRNAs) are short RNAs of around 22 nucleotides that regulate gene expression. The primary transcripts of miRNAs contain double-stranded RNA and are therefore potential substrates for adenosine to inosine (A-to-I) RNA editing...
  10. doi request reprint Exploring the genomes of cancer cells: progress and promise
    Michael R Stratton
    Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK
    Science 331:1553-8. 2011
    ..Here, I provide an overview of what these efforts have revealed to date about the origin and behavioral features of cancer cells and how this genomic information is being exploited to improve diagnosis and therapy of the disease...
  11. pmc Mutation analysis of 24 known cancer genes in the NCI-60 cell line set
    Ogechi N Ikediobi
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom
    Mol Cancer Ther 5:2606-12. 2006
    ....
  12. pmc The cancer genome
    Michael R Stratton
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
    Nature 458:719-24. 2009
    ..These studies will provide us with a detailed and comprehensive perspective on how individual cancers have developed...
  13. pmc A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers
    Deborah Thompson
    Genetic Epidemiology Unit, Strangeways Research Laboratories, University of Cambridge, Worts Causeway, Cambridge, CB1 8RN, United Kingdom
    Cancer Epidemiol Biomarkers Prev 15:2542-5. 2006
    ..Our results suggest that the risk of cancer associated with CHEK2 1100delC mutations is restricted to breast cancer, although we cannot rule out a small increase in overall cancer risk...
  14. ncbi request reprint Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization
    Goran Jonsson
    Department of Oncology, University Hospital, Lund, Sweden
    Cancer Res 65:7612-21. 2005
    ..00005, respectively). Further validation may prove this tumor classifier to be useful for selecting familial breast cancer cases for further mutation screening, particularly, as these data can be obtained using archival tissue...